Outcome of silicone oil tamponade combined dexamethasone implantation in patients with proliferative diabetic retinopathy and retinal detachment undergoing vitrectomy: a prospective randomized controlled clinical trial.

IF 1.7 4区 医学 Q3 OPHTHALMOLOGY
Yu Cao, Bohao Wang, Muzi Li, Aimin Sun, Tsung-I Wang, Jiyang Tang, Siying Li, Jinfeng Qu
{"title":"Outcome of silicone oil tamponade combined dexamethasone implantation in patients with proliferative diabetic retinopathy and retinal detachment undergoing vitrectomy: a prospective randomized controlled clinical trial.","authors":"Yu Cao, Bohao Wang, Muzi Li, Aimin Sun, Tsung-I Wang, Jiyang Tang, Siying Li, Jinfeng Qu","doi":"10.1186/s12886-025-04344-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report the outcome of adjunctive intravitreal dexamethasone (Ozurdex) implantation in patients with proliferative diabetic retinopathy (PDR) and retinal detachment (RD) undergoing vitrectomy and silicone oil (SO) tamponade.</p><p><strong>Design: </strong>A one-year, single-center, prospective, randomized controlled clinical trial.</p><p><strong>Methods: </strong>A total of 30 people (34 eyes) with PDR and RD who need vitrectomy and silicone oil tamponade were randomly assigned as 1:1 to study group and control group. Eyes in study group were injected with Ozurdex after vitrectomy and just before silicone oil tamponade. Primary outcome was the changes of epiretinal proliferative membranes area from 1 month to 12 months after the first operation. Anatomical and functional outcomes were also assessed during follow-up.</p><p><strong>Results: </strong>There was no significant difference in baseline characteristics between the two groups. The incidence of preretinal proliferation progression from 1-month to 12-months follow-up in the study group was significantly lower than that in the control group (23.5% vs. 88.2%, p=0.000). The area of preretinal proliferation in the study group was significantly smaller than that in the control group at 1-month, 3-months, 6-months, and 12-months follow-up and this difference increased with the prolongation of follow-up time. During the follow-up period, the incidence of macular epiretinal membrane in the study group (11.8%) was significantly lower than that in the control group (41.2%) (p=0.024). The mean best corrected visual acuity (BCVA) between the two groups only showed a significant difference at 12-months follow-up, with better BCVA in study group (0.61±0.70 logMAR) than in the control group (1.02±1.00 logMAR) (p=0.024). The mean central retinal thickness (CRT) of the study group at 1 and 6 months were 225.9 ± 106.9 µm and 223.0±118.9 µm respectively which was significantly lower than that of the control group (450.8 ± 301.4 µm and 275.5±131.9 µm, p=0.008 and 0.024, respectively).</p><p><strong>Conclusion: </strong>In patients with proliferative diabetes retinopathy complicated with retinal detachment, the combination of vitrectomy with silicone oil tamponade and dexamethasone implantation can reduce the incidence of preretinal proliferative membrane and macular epiretinal membrane and improve the visual outcome during 1 year follow-up.</p>","PeriodicalId":9058,"journal":{"name":"BMC Ophthalmology","volume":"25 1","pages":"523"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486658/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12886-025-04344-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report the outcome of adjunctive intravitreal dexamethasone (Ozurdex) implantation in patients with proliferative diabetic retinopathy (PDR) and retinal detachment (RD) undergoing vitrectomy and silicone oil (SO) tamponade.

Design: A one-year, single-center, prospective, randomized controlled clinical trial.

Methods: A total of 30 people (34 eyes) with PDR and RD who need vitrectomy and silicone oil tamponade were randomly assigned as 1:1 to study group and control group. Eyes in study group were injected with Ozurdex after vitrectomy and just before silicone oil tamponade. Primary outcome was the changes of epiretinal proliferative membranes area from 1 month to 12 months after the first operation. Anatomical and functional outcomes were also assessed during follow-up.

Results: There was no significant difference in baseline characteristics between the two groups. The incidence of preretinal proliferation progression from 1-month to 12-months follow-up in the study group was significantly lower than that in the control group (23.5% vs. 88.2%, p=0.000). The area of preretinal proliferation in the study group was significantly smaller than that in the control group at 1-month, 3-months, 6-months, and 12-months follow-up and this difference increased with the prolongation of follow-up time. During the follow-up period, the incidence of macular epiretinal membrane in the study group (11.8%) was significantly lower than that in the control group (41.2%) (p=0.024). The mean best corrected visual acuity (BCVA) between the two groups only showed a significant difference at 12-months follow-up, with better BCVA in study group (0.61±0.70 logMAR) than in the control group (1.02±1.00 logMAR) (p=0.024). The mean central retinal thickness (CRT) of the study group at 1 and 6 months were 225.9 ± 106.9 µm and 223.0±118.9 µm respectively which was significantly lower than that of the control group (450.8 ± 301.4 µm and 275.5±131.9 µm, p=0.008 and 0.024, respectively).

Conclusion: In patients with proliferative diabetes retinopathy complicated with retinal detachment, the combination of vitrectomy with silicone oil tamponade and dexamethasone implantation can reduce the incidence of preretinal proliferative membrane and macular epiretinal membrane and improve the visual outcome during 1 year follow-up.

Abstract Image

Abstract Image

Abstract Image

硅油填塞联合地塞米松植入治疗玻璃体切除术中增殖性糖尿病视网膜病变和视网膜脱离患者的疗效:一项前瞻性随机对照临床试验。
目的:报道增殖性糖尿病视网膜病变(PDR)合并视网膜脱离(RD)行玻璃体切除术和硅油(SO)填塞的患者辅助玻璃体内地塞米松(Ozurdex)植入术的疗效。设计:一项为期一年、单中心、前瞻性、随机对照临床试验。方法:将需要玻璃体切除术和硅油填塞的PDR和RD患者30例(34只眼)按1:1的比例随机分为研究组和对照组。实验组在玻璃体切除术后和硅油填塞前注射Ozurdex。主要观察指标为第一次手术后1 ~ 12个月视网膜增生膜面积的变化。在随访期间还对解剖和功能结果进行了评估。结果:两组患者的基线特征无显著差异。研究组随访1 ~ 12个月的视网膜前增殖进展发生率明显低于对照组(23.5% vs. 88.2%, p=0.000)。研究组在随访1个月、3个月、6个月、12个月时视网膜前增生面积均明显小于对照组,且随随访时间延长差异增大。随访期间,研究组黄斑视网膜前膜发生率(11.8%)显著低于对照组(41.2%)(p=0.024)。两组平均最佳矫正视力(BCVA)仅在随访12个月时有显著差异,研究组(0.61±0.70 logMAR)优于对照组(1.02±1.00 logMAR) (p=0.024)。研究组1个月和6个月视网膜中央厚度(CRT)均值分别为225.9±106.9µm和223.0±118.9µm,显著低于对照组(450.8±301.4µm和275.5±131.9µm, p分别=0.008和0.024)。结论:玻璃体切除术联合硅油填塞和地塞米松植入术对增殖性糖尿病视网膜病变合并视网膜脱离患者可降低视网膜前增生性膜和黄斑视网膜前膜的发生率,改善1年随访视力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Ophthalmology
BMC Ophthalmology OPHTHALMOLOGY-
CiteScore
3.40
自引率
5.00%
发文量
441
审稿时长
6-12 weeks
期刊介绍: BMC Ophthalmology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of eye disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信